1. The STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression) enrolled patients who did not remit on Step 1 citalopram and randomized them to Step 2 treatment options. Which of the following correctly describes the Step 2 design?
A) Step 2 randomized all non-remitters to ECT (electroconvulsive therapy) versus continued citalopram at maximum dose, establishing ECT as the preferred second-line intervention
B) Step 2 offered only switching options — replacing citalopram with a different antidepressant — because the trial protocol prohibited adding a second drug to a failed first-line agent
C) Step 2 offered both augmentation arms (adding bupropion or buspirone to citalopram) and switch arms (replacing citalopram with sertraline, bupropion, venlafaxine, or cognitive therapy), allowing patients to choose their preferred strategy based on willingness to discontinue the Step 1 drug
D) Step 2 required all patients to switch to a TCA (tricyclic antidepressant), reflecting the trial's hypothesis that serotonin-selective agents were insufficient for treatment-resistant patients
E) Step 2 was limited to lithium augmentation, which was selected as the sole comparator because of its established evidence base from pre-STAR*D augmentation trials
ANSWER: C
Rationale:
Option C is correct. STAR*D's Step 2 design was deliberately pragmatic: it offered patients who had not remitted on Step 1 citalopram a choice between augmentation (adding a second agent to citalopram — either bupropion or buspirone) and switching (replacing citalopram entirely — options included sertraline, bupropion, venlafaxine XR, or cognitive therapy). Patients who were unwilling to stop citalopram were directed to augmentation arms; those willing to discontinue could enter switch arms. This design reflected real-world clinical decision-making, where patient preference and degree of partial response both influence the augmentation-versus-switch choice. Importantly, no augmentation strategy proved superior to any switch strategy in Step 2, supporting clinical equipoise between the two approaches when partial response is present.
Option A: Option A is incorrect because ECT was not a Step 2 option in STAR*D; it was an available treatment outside the trial protocol but was not randomized as a Step 2 comparator.
Option B: Option B is incorrect because augmentation was explicitly offered at Step 2 alongside switching; the trial was specifically designed to evaluate both strategies.
Option D: Option D is incorrect because TCAs were not mandated at Step 2; they appeared as an option at Step 3 (nortriptyline), not as a required Step 2 intervention.
Option E: Option E is incorrect because lithium augmentation appeared at Step 3 of STAR*D, not Step 2; Step 2 augmentation options were bupropion and buspirone.
2. A key finding of the STAR*D trial was the cumulative remission rate observed across all four sequential treatment steps. Which of the following correctly states the cumulative remission rate and its most important clinical implication?
A) Approximately 90% of patients achieved remission by Step 4, demonstrating that persistence through sequential treatment almost universally succeeds and justifying aggressive pursuit of remission regardless of step count
B) Approximately 40% of patients achieved remission across all four steps, confirming that the majority of patients with MDD who fail first-line treatment will never achieve remission regardless of subsequent interventions
C) Approximately 50% of patients achieved remission at Step 1 alone, making subsequent steps necessary for only the minority with true pharmacological resistance
D) Approximately 25% of patients achieved remission across all four steps, establishing that sequential treatment algorithms provide minimal additional benefit beyond the first treatment attempt
E) Approximately 67% of patients achieved remission across all four steps, but remission rates declined with each successive step and relapse rates increased — establishing that earlier steps are both more likely to succeed and more likely to produce durable remission than later steps
ANSWER: E
Rationale:
Option E is correct. The cumulative remission rate across all four STAR*D steps was approximately 67%, meaning that about two-thirds of patients eventually achieved remission when treated through up to four sequential treatment adjustments. However, this headline figure carries an important caveat: remission rates at each successive step declined substantially — from approximately 28% at Step 1 to approximately 25% at Step 2, 12% at Step 3, and 13% at Step 4 — and relapse rates among patients who did achieve remission increased progressively with each successive step. Patients who required Step 3 or Step 4 to achieve remission had substantially higher relapse rates during follow-up than those who remitted at Step 1 or Step 2. The clinical implication is that achieving remission early — at Step 1 or Step 2 — produces the most durable outcomes, while later-step remissions, though real, are more fragile and require more intensive maintenance.
Option A: Option A is incorrect because a 90% cumulative rate substantially overstates the STAR*D finding; approximately one-third of patients did not achieve remission across all four steps.
Option B: Option B is incorrect because approximately 67%, not 40%, achieved cumulative remission; and characterizing the majority as never achieving remission misrepresents the trial's findings.
Option C: Option C is incorrect because Step 1 remission was approximately 28% — not 50%; a 50% rate would reflect the more optimistic outcomes of industry-sponsored trials with selected populations.
Option D: Option D is incorrect because a 25% cumulative rate dramatically understates STAR*D's findings; sequential treatment nearly tripled the remission yield compared to a single step.
3. Before concluding that a patient has failed an antidepressant trial, the clinician must confirm that the trial was adequate. Which of the following correctly defines the minimum requirements for an adequate antidepressant trial?
A) An adequate trial requires administration of the antidepressant at a therapeutic dose — at or above the minimum effective dose established in clinical trials — for a sufficient duration, generally defined as four to eight weeks at that dose, before response can be reliably assessed
B) An adequate trial requires a minimum of twelve weeks at any dose the patient tolerates, because individual pharmacokinetic variability means that some patients require extended time to achieve steady-state concentrations
C) An adequate trial is defined solely by plasma drug concentration reaching the published therapeutic range, regardless of the duration of exposure at that concentration
D) An adequate trial requires the patient to have tried the drug at the maximum approved labeled dose for at least six months before a switch or augmentation is considered
E) An adequate trial is defined as any course of treatment during which the patient took the medication consistently for at least two weeks, since clinical response should be detectable within the first two weeks if the drug is going to work
ANSWER: A
Rationale:
Option A is correct. An adequate antidepressant trial requires two components to be satisfied simultaneously: dose adequacy and duration adequacy. Dose adequacy means the antidepressant was administered at a dose at or above the minimum therapeutic threshold established in clinical evidence — not a subtherapeutic starting dose that was never uptitrated. Duration adequacy generally means maintaining that therapeutic dose for at least four to eight weeks before assessing response, because the neuroplastic and receptor-adaptive mechanisms underlying antidepressant efficacy require weeks to develop. The four-to-eight-week minimum reflects the time course of BDNF upregulation, autoreceptor desensitization, and downstream synaptic remodeling. A trial discontinued at two or three weeks because of impatience or premature assessment of non-response does not qualify as adequate. These two requirements together — therapeutic dose for sufficient duration — are the operational criteria used in TRD research and in the regulatory definition underlying esketamine approval.
Option B: Option B is incorrect because twelve weeks is not the standard minimum; four to eight weeks at therapeutic dose is the widely accepted criterion, and the rationale of pharmacokinetic variability alone does not extend the required duration to twelve weeks.
Option C: Option C is incorrect because plasma concentration alone does not define an adequate trial; adequate duration at therapeutic concentration is required, and plasma level monitoring is not routine for most antidepressants.
Option D: Option D is incorrect because the maximum labeled dose is not required; therapeutic dose — which may be well below the maximum — is sufficient, and six months substantially exceeds the standard minimum duration.
Option E: Option E is incorrect because two weeks is insufficient to assess antidepressant response; the neuroplastic mechanisms of antidepressant action require a minimum of four weeks and often longer to produce detectable clinical change.
4. Aripiprazole and brexpiprazole are both FDA-approved as augmenting agents for major depressive disorder. Which of the following correctly distinguishes these two agents while accurately describing their shared pharmacological basis?
A) Aripiprazole and brexpiprazole both act as full D2 agonists in the prefrontal cortex; brexpiprazole is preferred because it has a shorter half-life that allows more flexible dosing adjustments during augmentation
B) Both agents are partial agonists at dopamine D2 and serotonin 5-HT1A receptors combined with 5-HT2A antagonism; brexpiprazole has lower intrinsic activity at D2 receptors and higher relative 5-HT2A and alpha-1 adrenergic receptor affinity compared to aripiprazole, which translates to a lower incidence of akathisia — the restless, driven-to-move adverse effect that limits aripiprazole tolerability in some patients
C) Aripiprazole acts through dopaminergic mechanisms exclusively, while brexpiprazole acts through serotonergic mechanisms exclusively; their combination in augmentation provides full monoaminergic coverage that neither drug alone achieves
D) Both agents require therapeutic drug monitoring of plasma concentrations to prevent D2 receptor supersensitivity during long-term augmentation therapy
E) Brexpiprazole is a prodrug that requires hepatic conversion to an active aripiprazole metabolite; the two drugs are therefore pharmacodynamically identical but differ only in their route of activation
ANSWER: B
Rationale:
Option B is correct. Aripiprazole and brexpiprazole share the same fundamental pharmacological scaffold: both are partial agonists at dopamine D2 and D3 receptors and at serotonin 5-HT1A receptors, combined with antagonism at 5-HT2A receptors. This shared mechanism explains their shared antidepressant augmentation efficacy. The clinically meaningful difference lies in receptor binding profile details: brexpiprazole has lower intrinsic activity (partial agonist efficacy) at D2 receptors and relatively higher affinity at 5-HT2A and alpha-1B adrenergic receptors compared to aripiprazole. The lower D2 intrinsic activity of brexpiprazole is associated with a substantially lower incidence of akathisia — the subjective sense of inner restlessness and compulsion to move that represents one of the most common reasons for aripiprazole discontinuation in augmentation practice, occurring in approximately 10–25% of patients at augmenting doses. For patients who cannot tolerate aripiprazole's akathisia, brexpiprazole offers mechanistically equivalent augmentation with improved tolerability.
Option A: Option A is incorrect because both agents are partial agonists, not full agonists, at D2 receptors; full D2 agonism would produce dopaminergic excess effects inconsistent with clinical use.
Option C: Option C is incorrect because both agents have both dopaminergic and serotonergic receptor activities; neither is exclusively dopaminergic or serotonergic.
Option D: Option D is incorrect because routine therapeutic drug monitoring of plasma concentrations is not standard practice for aripiprazole or brexpiprazole augmentation; dose adjustment is guided by clinical response and tolerability.
Option E: Option E is incorrect because brexpiprazole is not a prodrug converted to aripiprazole; it is a distinct chemical entity with its own pharmacological profile and is not metabolized to aripiprazole.
5. Lithium augmentation of antidepressant therapy requires specific monitoring because of lithium's narrow therapeutic index. Which of the following correctly describes the pharmacokinetic basis for this requirement and the clinical monitoring it necessitates?
A) Lithium is extensively metabolized by CYP3A4 (cytochrome P450 3A4) in the liver; monitoring requires quarterly CYP3A4 activity assays to detect enzyme induction or inhibition that could alter lithium exposure
B) Lithium has a wide therapeutic window similar to SSRIs; monitoring is recommended only if the patient develops clinical signs of toxicity such as tremor or confusion
C) Lithium undergoes extensive plasma protein binding; regular albumin levels are required to calculate the free fraction available for central nervous system penetration and therapeutic effect
D) Lithium is not metabolized and is eliminated entirely by renal excretion, competing with sodium reabsorption in the proximal tubule; its narrow therapeutic index — with therapeutic concentrations near toxic concentrations — requires regular serum level monitoring, renal function assessment, and attention to sodium and fluid status, since dehydration, low-sodium diets, and NSAIDs all reduce lithium clearance and can precipitate toxicity
E) Lithium has a half-life of approximately two hours, requiring multiple daily doses and frequent intraday plasma level measurements to maintain stable therapeutic concentrations during augmentation
ANSWER: D
Rationale:
Option D is correct. Lithium's pharmacokinetic profile is unique among psychiatric drugs: it is not protein-bound, not metabolized by hepatic enzymes, and is eliminated entirely by renal excretion. In the proximal tubule, lithium competes directly with sodium for reabsorption — when sodium is depleted (through dehydration, low-sodium diet, diuretic use, or vomiting and diarrhea), the kidney compensates by increasing proximal tubular sodium reabsorption and unavoidably reabsorbs more lithium along with it, raising plasma lithium concentrations toward toxic levels. This pharmacokinetic mechanism explains why conditions that deplete sodium or reduce renal perfusion — including NSAIDs, which reduce prostaglandin-mediated renal blood flow, and thiazide diuretics — can precipitate lithium toxicity at previously stable doses. The therapeutic range for lithium augmentation (0.6–0.8 mEq/L) lies close to the toxic range (above 1.2–1.5 mEq/L), requiring regular serum level monitoring (every three to six months when stable) and baseline and periodic renal function assessment. Early toxicity signs include coarse tremor, nausea, diarrhea, and ataxia; severe toxicity produces seizures and cardiac arrhythmias.
Option A: Option A is incorrect because lithium is not metabolized by CYP3A4 or any hepatic enzyme; drug interactions affecting lithium do so through renal mechanisms, not hepatic enzyme activity.
Option B: Option B is incorrect because lithium's therapeutic window is narrow, not wide; relying solely on clinical signs of toxicity without serum monitoring is unsafe given that early and late toxicity signs may overlap and toxicity can escalate rapidly.
Option C: Option C is incorrect because lithium has negligible plasma protein binding — essentially 0% — making albumin monitoring irrelevant to lithium management.
Option E: Option E is incorrect because lithium's half-life is approximately 18–24 hours in adults with normal renal function (not two hours), allowing once or twice daily dosing; intraday plasma level measurements are not required.
6. A patient has been diagnosed with treatment-resistant depression after failing two adequate antidepressant trials. Before initiating an intensive TRD protocol, the clinician screens for reversible medical causes of apparent treatment resistance. Which of the following represents a treatable medical condition that, if present and uncorrected, would constitute pseudo-resistance rather than true pharmacological refractoriness?
A) A family history of bipolar disorder in a first-degree relative, which indicates a genetic predisposition to antidepressant non-response that cannot be corrected by addressing medical comorbidities
B) A serum ferritin level in the lower half of the normal reference range, which indicates subclinical iron deficiency that specifically blocks antidepressant receptor binding
C) Hypothyroidism — even subclinical hypothyroidism with a TSH (thyroid-stimulating hormone) above the upper limit of normal — because thyroid hormone is required for normal serotonergic and noradrenergic receptor sensitivity, and untreated hypothyroidism can prevent adequate antidepressant response regardless of drug selection or dose
D) A polymorphism in the serotonin transporter promoter gene (5-HTTLPR) short allele, which reduces serotonin transporter expression and makes SSRIs less effective by reducing the density of their pharmacological target
E) A body mass index above 30, because obesity increases the volume of distribution of antidepressants to a degree that reduces brain penetration below therapeutic thresholds at standard doses
ANSWER: C
Rationale:
Option C is correct. Hypothyroidism — including subclinical hypothyroidism defined by an elevated TSH with normal free T4 — is one of the most important reversible medical causes of antidepressant non-response and is explicitly listed in clinical guidelines as a condition that must be excluded before concluding that a patient has true TRD. Thyroid hormone plays a critical role in regulating central nervous system serotonergic and noradrenergic receptor sensitivity and in supporting the neuroplastic changes that antidepressants depend on for their efficacy; hypothyroid states reduce the responsiveness of these systems in ways that blunt antidepressant drug action. Correction of hypothyroidism with levothyroxine can restore antidepressant responsiveness in patients who appeared pharmacologically refractory. Other reversible conditions in the pseudo-resistance differential include sleep apnea, chronic pain, inflammatory disease, substance use disorders, and inadequately treated anxiety disorders.
Option A: Option A is incorrect because a family history of bipolar disorder is a clinical risk factor warranting explicit screening for bipolar spectrum illness, not a fixed genetic predictor of non-response that constitutes pseudo-resistance in the sense described; it prompts diagnostic reassessment rather than medical treatment.
Option B: Option B is incorrect because subclinical iron deficiency within the normal ferritin reference range does not specifically block antidepressant receptor binding; while iron deficiency anemia can contribute to fatigue, it does not represent an established reversible cause of antidepressant non-response in the way hypothyroidism does.
Option D: Option D is incorrect because the 5-HTTLPR short allele polymorphism is a pharmacogenomic risk factor associated with reduced SSRI efficacy in some studies, but it is not a treatable medical condition and does not constitute pseudo-resistance in the reversible sense; it represents an inherent pharmacogenomic characteristic rather than a correctable medical comorbidity.
Option E: Option E is incorrect because while obesity does affect the volume of distribution of lipophilic drugs, antidepressants achieve adequate central nervous system penetration at standard doses across a wide range of body habitus, and obesity alone is not an established cause of pseudo-resistance.
7. ECT (electroconvulsive therapy) is highly effective for treatment-resistant depression but is associated with cognitive adverse effects that represent its primary clinical limitation. Which of the following correctly characterizes these cognitive effects?
A) ECT produces both anterograde amnesia (difficulty forming new memories during the acute treatment course) and retrograde amnesia (loss of memories from the period before and around treatment); both effects are most prominent during the acute treatment course and typically resolve fully within six months in most patients, though some patients report persistent autobiographical memory gaps
B) ECT produces permanent global cognitive impairment equivalent to moderate traumatic brain injury; this irreversible deficit is the reason ECT is reserved only for patients with life-threatening depression where no other option exists
C) ECT produces cognitive effects exclusively during the immediate postictal period following each session; between sessions, cognitive function returns fully to baseline, and no cumulative cognitive effects develop over the treatment course
D) ECT's cognitive effects are limited to working memory deficits that fully resolve within 24 hours of the final treatment session; autobiographical and long-term memory are not affected by the procedure
E) ECT produces cognitive effects only in patients over age 70; younger patients have sufficient neuroplastic reserve to compensate for the electrical stimulation without measurable memory impairment
ANSWER: A
Rationale:
Option A is correct. ECT's primary cognitive adverse effects are anterograde amnesia — impaired ability to form and retain new memories during the acute treatment course — and retrograde amnesia — loss of memories from the weeks to months surrounding the treatment period, including both personal autobiographical memories and more general semantic memories. Both effects are most pronounced during the acute treatment course (typically six to twelve sessions administered over two to four weeks) and in the weeks immediately following completion. The majority of patients experience full resolution of these cognitive effects within six months of treatment completion. However, a minority of patients report persistent gaps in autobiographical memory — particularly for events close in time to the treatment course — that do not fully recover; this represents the most clinically significant long-term concern with ECT and is a central element of informed consent. Electrode placement and stimulus parameters affect the severity of cognitive effects: bilateral electrode placement produces greater anterograde amnesia than right unilateral placement, while ultra-brief pulse stimulation produces fewer cognitive effects than standard brief pulse stimulation.
Option B: Option B is incorrect because ECT does not produce permanent global cognitive impairment equivalent to traumatic brain injury; characterizing it this way overstates the severity and permanence of the cognitive effects and misrepresents the substantial body of evidence showing cognitive recovery in the majority of patients.
Option C: Option C is incorrect because cumulative cognitive effects do develop over the course of ECT treatment; the effects are not limited to the immediate postictal period and do accumulate with successive sessions.
Option D: Option D is incorrect because retrograde amnesia affecting autobiographical memory is a well-documented effect of ECT that extends beyond working memory and does not fully resolve within 24 hours; this description substantially undercharacterizes the scope of ECT's cognitive effects.
Option E: Option E is incorrect because ECT-associated cognitive effects occur across all age groups; while older patients may have a more prolonged recovery, younger patients are not immune to anterograde and retrograde memory effects.
8. The FDA has cleared rTMS (repetitive transcranial magnetic stimulation) for major depressive disorder, but the treatment resistance threshold for FDA-cleared rTMS differs meaningfully from the threshold typically associated with ECT indication. Which of the following correctly states the FDA-cleared indication for rTMS and explains the clinical significance of that threshold?
A) rTMS is FDA-cleared for MDD only after failure of at least four adequate antidepressant trials — a higher threshold than ECT — because rTMS requires a longer treatment course and is only cost-effective in the most refractory patients
B) rTMS carries no FDA clearance for MDD; its use is entirely off-label and based on meta-analytic evidence rather than a regulatory approval pathway
C) rTMS is FDA-cleared for MDD after failure of at least three adequate antidepressant trials of different classes, placing it at the same treatment resistance threshold as esketamine
D) rTMS and ECT carry identical FDA treatment resistance thresholds, reflecting the regulatory view that both are equivalent-intensity somatic interventions requiring equivalent prior pharmacological failure
E) rTMS is FDA-cleared for MDD in patients who have failed at least one prior adequate antidepressant trial — a substantially lower treatment resistance threshold than ECT — meaning rTMS can be considered earlier in the treatment sequence than ECT and does not require the depth of pharmacological failure that ECT typically demands
ANSWER: E
Rationale:
Option E is correct. The FDA-cleared indication for rTMS in MDD specifies failure of at least one prior adequate antidepressant trial — a notably lower threshold than the two-or-more failed trials that define TRD for esketamine approval and the more advanced treatment resistance typically required before ECT is indicated. This lower clearance threshold has significant clinical implications: rTMS can be introduced after a single failed antidepressant trial, positioning it earlier in the treatment algorithm than ECT, without requiring the patient to have exhausted multiple pharmacological strategies. The absence of anesthesia, the lack of systemic drug effects, and the outpatient administration of rTMS also make it appropriate earlier in the treatment sequence compared to ECT, which is typically reserved for more severe or refractory presentations. In practice, many clinicians consider rTMS after one or two failed trials in patients who prefer to avoid medication burden or who have had intolerability issues, and before the full TRD threshold is reached.
Option A: Option A is incorrect because the rTMS threshold is lower than ECT's, not higher; the FDA-cleared indication requires one failed trial, not four.
Option B: Option B is incorrect because rTMS has FDA clearance for MDD, first granted in 2008 for the NeuroStar system; its use is not entirely off-label.
Option C: Option C is incorrect because the FDA-cleared rTMS indication specifies one failed trial, not three; equating it with the esketamine TRD threshold misrepresents the regulatory distinction between the two treatments.
Option D: Option D is incorrect because rTMS and ECT carry different treatment resistance thresholds; rTMS's one-failed-trial clearance is substantially less demanding than the clinical threshold typically associated with ECT indication.
9. Theta-burst stimulation (TBS) is a newer rTMS protocol that has received FDA clearance for MDD. Which of the following correctly describes TBS and its primary clinical advantage over standard rTMS protocols?
A) TBS uses a lower magnetic field intensity than standard rTMS, making it safer for patients with metallic implants who cannot receive standard rTMS due to device heating risks
B) TBS delivers stimulation in a compressed burst pattern that achieves comparable antidepressant efficacy to standard rTMS protocols but requires only three to ten minutes per session compared to the thirty-seven minutes of standard 10 Hz rTMS — substantially reducing treatment time per session and improving clinical feasibility
C) TBS targets the right prefrontal cortex using inhibitory stimulation patterns, whereas standard rTMS targets the left prefrontal cortex using excitatory stimulation — TBS is therefore preferred for patients with right-hemisphere depression subtypes identified on functional neuroimaging
D) TBS requires daily sessions for twelve consecutive months to achieve durable antidepressant response, whereas standard rTMS requires only six weeks of daily sessions; TBS's longer course makes it more effective but significantly more burdensome
E) TBS is a form of deep TMS using an H-coil that reaches subcortical structures; it is distinguished from surface rTMS by its ability to directly stimulate the hippocampus and normalize BDNF (brain-derived neurotrophic factor) expression in the limbic system
ANSWER: B
Rationale:
Option B is correct. Theta-burst stimulation is a compressed rTMS protocol in which magnetic pulses are delivered in brief high-frequency bursts (three pulses at 50 Hz, repeated at 5 Hz theta rhythm) rather than the continuous 10 Hz trains used in standard rTMS. The key clinical advantage is session duration: intermittent TBS (iTBS) applied to the left DLPFC (dorsolateral prefrontal cortex) achieves antidepressant efficacy comparable to standard 10 Hz rTMS protocols in approximately three minutes of stimulation per session, versus approximately thirty-seven minutes for standard protocols. The THREE-D trial demonstrated non-inferiority of iTBS compared to standard rTMS across multiple outcomes in MDD. This compressed administration substantially improves clinical workflow, reduces the burden on both patients and treatment facilities, and has enabled more flexible scheduling. FDA clearance for TBS was granted based on this non-inferiority evidence.
Option A: Option A is incorrect because TBS uses the same fundamental magnetic stimulation technology as standard rTMS and does not have a lower field intensity that would alter implant safety considerations; metallic implant safety is assessed by implant type and location, not by whether TBS or standard rTMS is used.
Option C: Option C is incorrect because TBS protocols target the same left DLPFC site as standard rTMS using excitatory iTBS patterns; while inhibitory cTBS (continuous theta-burst) exists experimentally, the FDA-cleared protocol uses iTBS at the left DLPFC, not right-hemisphere inhibitory stimulation.
Option D: Option D is incorrect because TBS uses the same overall treatment course duration as standard rTMS — typically four to six weeks of daily sessions — not a twelve-month course; the advantage is session duration (minutes), not overall course duration.
Option E: Option E is incorrect because TBS is a surface coil protocol applied to the scalp; deep TMS using the H-coil is a separate device technology (BrainsWay) that is distinct from TBS.
10. A patient achieves full remission on sertraline 200 mg daily after eight weeks of acute treatment. Her psychiatrist considers reducing the dose to 100 mg to minimize adverse effects during the continuation phase. Which of the following best describes the pharmacological rationale for or against this dose reduction?
A) Dose reduction is recommended at the start of the continuation phase because the neuroplastic changes that produced remission are now self-sustaining and no longer require the full therapeutic drug concentration to be maintained
B) Dose reduction is appropriate if the patient has experienced any adverse effects at the higher dose, because tolerability during maintenance is more important than maintaining the exact dose that produced remission
C) Dose reduction is required by all major clinical guidelines at the transition from acute to continuation phase, because prolonged exposure to high doses increases the risk of serotonin syndrome during the continuation period
D) Dose reduction during the continuation phase increases relapse risk without producing adverse effect reductions sufficient to justify the tradeoff; the antidepressant should be maintained at the same dose that produced remission throughout the continuation phase
E) Dose reduction is appropriate only if the patient's serum sertraline concentration exceeds the published therapeutic range, as measured by therapeutic drug monitoring at the transition to continuation phase
ANSWER: D
Rationale:
Option D is correct. The pharmacological principle governing the continuation phase is clear and consistent across clinical guidelines: the same dose of the antidepressant that produced remission should be maintained without reduction throughout the continuation phase. The rationale is mechanistic: the neuroplasticity-dependent adaptations that underlie remission — BDNF upregulation, dendritic spine maintenance, HPA axis normalization — appear to require continued drug exposure at the effective concentration to be sustained. Dose reduction during the continuation phase reduces drug exposure below the level that maintained those neuroplastic adaptations, increasing the probability that the biological substrate of the depressive episode reasserts itself before the episode has run its natural course. Clinical trial data confirm that dose reduction during continuation significantly increases relapse rates compared to maintaining the full remission dose. The adverse effect burden at effective antidepressant doses during maintenance is generally manageable, and the risk-benefit calculation consistently favors maintaining the full dose over dose reduction. If adverse effects at the remission dose are genuinely intolerable, the clinical decision should involve a frank discussion about the relapse risk rather than a routine dose reduction.
Option A: Option A is incorrect because the neuroplastic changes of remission are not self-sustaining at lower drug concentrations; they depend on continued adequate drug exposure, which is precisely why dose reduction increases relapse risk.
Option B: Option B is incorrect because adverse effect management during continuation does not justify dose reduction as a routine approach; tolerability concerns should be addressed through other means, and reducing the remission dose carries established relapse risk.
Option C: Option C is incorrect because no clinical guideline recommends dose reduction at the transition to continuation phase; the opposite is true — guidelines universally recommend maintaining the remission dose.
Option E: Option E is incorrect because routine therapeutic drug monitoring of sertraline plasma concentrations is not standard clinical practice for SSRIs, and dose decisions are not based on measured serum concentrations for this drug class.
11. Recurrence risk in major depressive disorder increases progressively with each successive depressive episode. Which of the following correctly states the approximate recurrence risk figures that guide maintenance therapy duration decisions?
A) The recurrence rate after a first depressive episode is approximately 50%; after two episodes, approximately 70%; after three or more episodes, approximately 90% — this escalating risk profile is the primary evidence base for recommending indefinite maintenance therapy after three or more lifetime episodes
B) The recurrence rate after a first depressive episode is approximately 10%; after two episodes, approximately 25%; after three or more episodes, approximately 50% — establishing that even highly recurrent depression carries only a moderate lifetime recurrence probability
C) Recurrence risk is uniform across episode count at approximately 30% per year regardless of prior episode history, meaning that episode count alone should not drive maintenance therapy decisions
D) The recurrence rate after a first depressive episode is approximately 80%, making indefinite maintenance therapy the recommended standard after any single episode in any patient
E) Recurrence risk is determined primarily by symptom severity during the index episode rather than episode count; patients with mild first episodes have less than 5% recurrence risk regardless of subsequent episode history
ANSWER: A
Rationale:
Option A is correct. The well-established recurrence risk figures for major depressive disorder — drawn from longitudinal naturalistic studies — show a stepwise escalation with each successive episode: approximately 50% after a first episode, approximately 70% after a second episode, and approximately 90% after three or more episodes. These figures reflect the biological kindling-like process in MDD, in which each successive depressive episode lowers the threshold for the next, increases the severity and duration of subsequent episodes, and reduces the probability of full interepisode recovery. The approximately 90% lifetime recurrence rate after three or more episodes is the primary evidence-based justification for recommending indefinite maintenance antidepressant therapy at that threshold — at a 90% recurrence probability, the expected harm from repeated depressive recurrences substantially outweighs the risks and burdens of long-term antidepressant maintenance for most patients.
Option B: Option B is incorrect because the recurrence risk figures stated — 10%, 25%, 50% — substantially underestimate the well-documented escalating recurrence rates; a 50% risk after three or more episodes would not support the strong guideline recommendation for indefinite maintenance.
Option C: Option C is incorrect because recurrence risk is not uniform across episode count; the stepwise increase with episode number is one of the most replicated findings in the naturalistic MDD literature and is the foundation of episode-count-based maintenance recommendations.
Option D: Option D is incorrect because while first-episode recurrence risk of approximately 50% is significant, it does not reach the 80% level stated, and it is not the threshold that triggers universal indefinite maintenance recommendations; the three-or-more-episode threshold with approximately 90% recurrence risk is the guideline-endorsed criterion.
Option E: Option E is incorrect because while episode severity is a relevant clinical factor in maintenance decisions, episode count is independently predictive of recurrence risk and is not subordinate to severity in guideline recommendations.
12. Quetiapine is used as an augmenting agent for MDD at doses that differ substantially from its antipsychotic dosing range. Which of the following correctly describes the dose relationship and explains its pharmacological basis?
A) Quetiapine augmentation uses the same dose range as antipsychotic treatment (400–800 mg daily) because the antidepressant-augmenting and antipsychotic effects are mediated by identical receptor occupancy requirements at D2 receptors
B) Quetiapine augmentation requires doses above 600 mg daily to achieve sufficient H1 (histamine type 1 receptor) blockade for its sedating and anxiolytic augmentation effects; lower doses produce only partial H1 occupancy insufficient for clinical benefit
C) Quetiapine augmentation for MDD uses doses of approximately 50–300 mg daily — substantially lower than the 400–800 mg range used for antipsychotic indications — because the H1 receptor blockade mediating sedation and anxiolysis, the 5-HT2A antagonism, and the partial 5-HT1A agonism that drive augmentation efficacy are achieved at lower receptor occupancies than the D2 blockade required for antipsychotic effect
D) Quetiapine doses used for MDD augmentation are identical to its antipsychotic doses; the distinction is in the duration of treatment rather than dose, with augmentation requiring shorter courses than antipsychotic maintenance therapy
E) Quetiapine augmentation is initiated at 25 mg but must be rapidly titrated to a minimum of 500 mg within two weeks to achieve sufficient antidepressant receptor occupancy; slower titration is associated with therapeutic failure
ANSWER: C
Rationale:
Option C is correct. Quetiapine's receptor pharmacology operates across a dose-dependent hierarchy: at lower doses (50–150 mg), H1 receptor blockade and 5-HT2A antagonism predominate, producing sedating, anxiolytic, and serotonin system-modulating effects with minimal D2 receptor occupancy. As doses increase toward the antipsychotic range (400–800 mg), D2 receptor blockade becomes increasingly prominent and produces the antipsychotic effects required for schizophrenia and bipolar mania treatment. For MDD augmentation, the therapeutic targets — sedating H1 blockade addressing insomnia, 5-HT2A antagonism disinhibiting dopaminergic and noradrenergic release in the prefrontal cortex, and partial 5-HT1A agonism contributing anxiolytic effects — are achieved at the lower dose range of 50–300 mg daily without requiring the high D2 occupancy of antipsychotic dosing. This dose separation means that quetiapine augmentation can provide meaningful antidepressant enhancement with a substantially more favorable extrapyramidal and prolactin-related adverse effect profile than antipsychotic doses would carry, though metabolic effects (weight gain, dyslipidemia) and sedation remain relevant at all doses.
Option A: Option A is incorrect because augmentation does not use the antipsychotic dose range; the pharmacological targets for augmentation are achieved at substantially lower doses than D2 blockade requires.
Option B: Option B is incorrect because H1 receptor blockade — which has high affinity and is achieved at low doses — does not require doses above 600 mg; H1 occupancy is among the first receptor effects to emerge as quetiapine dose increases, not one requiring high doses.
Option D: Option D is incorrect because the dose distinction is real and clinically meaningful; augmentation doses (50–300 mg) and antipsychotic doses (400–800 mg) are not identical, and the difference is pharmacologically grounded, not simply a matter of treatment duration.
Option E: Option E is incorrect because quetiapine augmentation does not require rapid titration to 500 mg; augmentation is initiated at low doses (25–50 mg) and titrated cautiously to effect within the 50–300 mg range.
13. When selecting buspirone as an augmenting agent for an SSRI partial responder whose residual symptoms are predominantly anxiety, which of the following pharmacological characteristics of buspirone makes it specifically preferable to benzodiazepine augmentation in this clinical context?
A) Buspirone produces faster anxiolytic onset than benzodiazepines — typically within two hours of the first dose — making it more suitable for patients whose residual anxiety requires immediate relief
B) Buspirone has a longer half-life than all available benzodiazepines, allowing once-weekly dosing that improves adherence in patients already managing multiple daily antidepressant doses
C) Buspirone potentiates GABA (gamma-aminobutyric acid) receptor activity through a benzodiazepine-binding site mechanism, but with lower receptor efficacy that produces anxiolysis without the sedation associated with full benzodiazepine agonists
D) Buspirone irreversibly binds the 5-HT1A receptor, producing a permanent receptor modification that eliminates the need for continuous daily dosing after an initial loading period
E) Buspirone produces anxiolytic effects without physical dependence, withdrawal syndrome, respiratory depression, or the cognitive impairment associated with benzodiazepines — making it the preferred option for augmenting antidepressant therapy in patients with residual anxiety, particularly those with comorbid anxiety disorders, substance use history, or respiratory compromise where benzodiazepine risks are unacceptable
ANSWER: E
Rationale:
Option E is correct. Buspirone's most clinically important distinguishing characteristic relative to benzodiazepines is its safety profile: it does not act at the GABA-A receptor/benzodiazepine binding site, and therefore produces none of the pharmacological consequences of GABA-A potentiation — no physical dependence, no physiological withdrawal syndrome on discontinuation, no respiratory depression, and no clinically significant cognitive or psychomotor impairment at therapeutic doses. This profile makes buspirone specifically suitable for augmenting antidepressant therapy in patients with residual anxiety who have a history of substance use disorder (where benzodiazepine dependence risk is elevated), comorbid respiratory disease such as COPD or sleep apnea (where respiratory depression is particularly hazardous), occupational requirements for cognitive sharpness, or who simply cannot safely receive a dependence-producing anxiolytic as part of a long-term antidepressant regimen. The tradeoff is that buspirone's anxiolytic onset requires two to four weeks of consistent dosing — it has no immediate anxiolytic effect, unlike benzodiazepines — which must be communicated to patients expecting rapid relief.
Option A: Option A is incorrect because buspirone does not produce rapid anxiolytic onset; its effects develop over two to four weeks of consistent dosing, which is substantially slower than the near-immediate anxiolysis of benzodiazepines, making it unsuitable for patients requiring immediate relief.
Option B: Option B is incorrect because buspirone has a short half-life of approximately two to three hours requiring two to three daily doses; once-weekly dosing is not feasible with this pharmacokinetic profile.
Option C: Option C is incorrect because buspirone does not act at the GABA-A receptor or benzodiazepine binding site; its mechanism is entirely through 5-HT1A partial agonism and weak D2 partial agonism, not through GABA-A modulation.
Option D: Option D is incorrect because buspirone does not irreversibly bind the 5-HT1A receptor; it is a reversible partial agonist, and daily dosing is required throughout treatment to maintain its anxiolytic and augmenting effects.
14. A patient with MDD has failed three adequate antidepressant trials of different classes, has not tried augmentation strategies, and has been depressed for fourteen months. Her Maudsley Staging Method (MSM) score is calculated as 8. Which of the following correctly interprets this score and its clinical implications?
A) An MSM score of 8 falls in the mild TRD category and indicates that the patient's treatment history does not yet meet the threshold for specialist referral or consideration of esketamine or ECT
B) An MSM score of 8 falls in the moderate TRD category (scores 7–10), indicating a treatment history associated with lower probability of response to subsequent pharmacological steps, longer expected time to remission, and a clinical profile that warrants consideration of specialist referral, esketamine, or ECT evaluation
C) An MSM score of 8 falls in the severe TRD category and mandates immediate ECT referral without further pharmacological trials, as scores above 7 indicate that pharmacotherapy has been exhausted
D) The MSM score of 8 has no clinical implications because the MSM is a research instrument without validated clinical cut-points; it cannot be used to guide individual treatment decisions
E) An MSM score of 8 indicates that the patient has a high inflammatory burden as measured by serum biomarkers; this score triggers automatic referral for CRP (C-reactive protein) and IL-6 testing to confirm the inflammatory subtype of TRD
ANSWER: B
Rationale:
Option B is correct. The Maudsley Staging Method assigns patients to three categories based on their total score: mild TRD (scores 2–6), moderate TRD (scores 7–10), and severe TRD (scores 11–15). A score of 8 places this patient in the moderate TRD category. This staging carries prognostic information: moderate TRD is associated with substantially lower response probability to the next treatment step compared to mild TRD, and with longer expected time to remission even if remission is ultimately achieved. Clinically, the moderate category identifies patients who are most likely to benefit from psychiatric specialist consultation, systematic reassessment of treatment history for gaps (such as whether lithium augmentation has been tried), evaluation for esketamine candidacy, and ECT evaluation — particularly if the clinical situation is urgent due to symptom severity, suicidality, or functional incapacitation. The MSM score does not prescribe a specific treatment algorithm but provides a structured framework for communicating treatment resistance severity and guiding the intensity of the next intervention.
Option A: Option A is incorrect because a score of 8 falls in the moderate category (7–10), not mild (2–6); mild TRD corresponds to scores 2–6, and an 8 exceeds that range.
Option C: Option C is incorrect because the severe TRD category corresponds to scores 11–15, not scores above 7; a score of 8 is moderate, and the MSM does not mandate immediate ECT referral at any score threshold.
Option D: Option D is incorrect because the MSM has validated clinical cut-points and does provide clinically actionable prognostic and treatment guidance; characterizing it as purely a research instrument without clinical applicability misrepresents its established use.
Option E: Option E is incorrect because the MSM scores treatment resistance history — trial count, duration, augmentation, and ECT history — not inflammatory biomarkers; serum CRP and IL-6 are separate research and clinical assessments not incorporated into the MSM scoring system.
15. Research into the biological features of true TRD has identified inflammatory biomarkers as predictors of differential antidepressant response. Which of the following correctly describes the clinical significance of elevated CRP (C-reactive protein) in a patient with MDD being assessed for treatment resistance?
A) Elevated CRP above 3 mg/L is a contraindication to SSRI therapy because CRP directly inhibits the serotonin reuptake transporter, rendering SSRIs pharmacologically ineffective in the presence of systemic inflammation
B) Elevated CRP in MDD indicates that the patient's depression is caused entirely by a primary inflammatory disease such as rheumatoid arthritis or inflammatory bowel disease; antidepressants are ineffective and the inflammatory disease must be treated first before any psychiatric pharmacotherapy is initiated
C) Elevated CRP above 3 mg/L predicts superior response to SSRIs compared to other antidepressant classes, because systemic inflammation upregulates serotonin transporter expression and increases the pharmacological target density for SSRI binding
D) Elevated CRP above 3 mg/L predicts poor response to SSRIs in MDD and may predict relatively better response to antidepressants with anti-inflammatory properties or to bupropion; this inflammatory subtype of TRD reflects impaired neuroplasticity driven by cytokine-mediated suppression of BDNF (brain-derived neurotrophic factor) expression and HPA (hypothalamic-pituitary-adrenal) axis dysregulation
E) CRP is not a clinically relevant biomarker in TRD because inflammatory markers fluctuate too rapidly with intercurrent infections to provide stable predictive information about antidepressant response
ANSWER: D
Rationale:
Option D is correct. Elevated CRP above 3 mg/L — a threshold corresponding to low-grade chronic systemic inflammation rather than acute infectious inflammation — has been identified in multiple studies as a predictor of poor SSRI response in MDD and as a potential identifier of an inflammatory subtype of depression. The biological mechanism involves cytokine-mediated effects on the neuroplasticity pathways that antidepressants depend on: pro-inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) suppress BDNF expression, impair hippocampal neurogenesis, activate the HPA axis driving hypercortisolemia, and alter tryptophan metabolism through the kynurenine pathway — collectively creating a biological environment resistant to SSRI-driven neuroplasticity. Patients with high-inflammation MDD may respond better to antidepressants with anti-inflammatory properties (such as certain TCAs or minocycline in research settings) or to bupropion, which has some evidence of relative efficacy in high-CRP MDD. While inflammatory biomarker-guided antidepressant selection is not yet part of routine clinical algorithms, CRP measurement is increasingly studied as a practical, widely available biomarker for stratifying MDD treatment.
Option A: Option A is incorrect because CRP does not directly inhibit the serotonin reuptake transporter; its effects on SSRI response are indirect, mediated through downstream biological consequences of chronic inflammation rather than pharmacokinetic interference with drug binding.
Option B: Option B is incorrect because elevated CRP in MDD does not mandate a primary inflammatory disease diagnosis; low-grade neuroinflammation is increasingly recognized as a feature of a subtype of MDD itself, and antidepressants are not categorically ineffective in patients with elevated inflammatory markers.
Option C: Option C is incorrect because elevated CRP predicts poor SSRI response, not superior response; upregulation of serotonin transporter expression by inflammation would, if anything, increase the pharmacological challenge for SSRIs by providing more transporter molecules to overcome.
Option E: Option E is incorrect because CRP from low-grade chronic inflammation is a relatively stable biomarker when measured in the absence of intercurrent acute illness; research validating its predictive value in MDD specifically uses chronic elevation thresholds and excludes acute inflammatory states.
16. STAR*D pioneered the systematic application of measurement-based care (MBC) in real-world antidepressant practice, using a specific validated instrument to track symptom severity at every clinical contact and guide treatment decisions. Which instrument served this role in STAR*D, and what was its design feature that made it practical for systematic use across a large outpatient trial?
A) The Hamilton Depression Rating Scale (HDRS-17), administered by trained research clinicians at every visit, was selected because clinician-rated instruments are more sensitive to antidepressant-induced symptom change than self-report measures in outpatient populations
B) The Montgomery-Asberg Depression Rating Scale (MADRS), a ten-item clinician-rated scale, was used because its focused assessment of cognitive symptoms and suicidality provided the most clinically actionable information for sequential treatment decisions
C) The Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16), a sixteen-item self-report scale assessing all nine DSM criteria for MDD, was used because it could be completed by patients before or during clinic visits without requiring a trained rater — making systematic symptom monitoring feasible at every clinical contact across a large pragmatic trial
D) The Beck Depression Inventory-II (BDI-II) was used because it is the only self-report depression scale validated for both screening and treatment monitoring in the specific STAR*D outpatient population
E) The PHQ-9 was developed specifically for STAR*D and subsequently validated for general clinical use; its nine-item structure was designed to map directly onto the DSM criteria for MDD as tested in the trial's sequential treatment protocol
ANSWER: C
Rationale:
Option C is correct. STAR*D used the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16) as its primary measurement-based care instrument. The QIDS-SR16 is a sixteen-item self-report scale that assesses all nine DSM criterion domains for major depressive disorder — sleep, energy, appetite, concentration, psychomotor changes, interest, guilt/worthlessness, suicidality, and mood — with multiple items assessing sleep and appetite to capture the full range of neurovegetative symptom variation. Its self-report design was central to STAR*D's pragmatic approach: patients could complete the QIDS-SR16 before or during each clinic visit without requiring a trained clinician rater, making it feasible to obtain standardized symptom data at every clinical contact across more than 4,000 patients at forty-one clinical sites. Clinicians used QIDS-SR16 scores in real time to guide dose adjustments and treatment step decisions — the essence of measurement-based care. The Hamilton Depression Rating Scale (HDRS) was also used in STAR*D as a secondary outcome measure.
Option A: Option A is incorrect because while the HDRS-17 was used in STAR*D as a secondary measure, it was not the primary MBC instrument driving clinical decisions; the QIDS-SR16's self-report design made it the practical instrument for systematic visit-by-visit monitoring.
Option B: Option B is incorrect because the MADRS was not the primary instrument used in STAR*D; it is a valid depression rating scale widely used in European clinical trials but was not the measurement-based care tool central to STAR*D's design.
Option D: Option D is incorrect because the BDI-II was not the primary STAR*D instrument; the QIDS-SR16 was developed and used specifically because it maps onto DSM criteria domains and was designed for the measurement-based care application that STAR*D required.
Option E: Option E is incorrect because the PHQ-9 was not developed for STAR*D; it was developed by Spitzer and colleagues and published in 2001 as a primary care depression screening and monitoring tool, predating and independent of STAR*D's design.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.